HUTCHMED (China) (HMDCF) Other Accumulated Expenses (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Other Accumulated Expenses came in at $4.5 million in Q2 2026, down 12.47% year-over-year from $5.1 million in Q2 2025, and down 9.77% quarter-over-quarter from $5.0 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Other Accumulated Expenses for 12 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Accumulated Expenses fell 12.47% year-over-year to $4.5 million in Q2 2026; TTM through Jun 2026 was $4.5 million, a 12.47% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, down 60.21% from the prior year.
- Other Accumulated Expenses was $4.5 million for Q2 2026 at HUTCHMED (China), down from $5.0 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $37.2 million in Q2 2022 and troughed at $4.5 million in Q2 2026.
- A 5-year average of $11.1 million and a median of $6.8 million in 2023 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses jumped 443.17% in 2022 and plunged 81.71% in 2023, its largest moves.
- Over 5 years, Other Accumulated Expenses stood at $12.2 million in 2022, then decreased by 14.2% to $10.5 million in 2023, then increased by 19.09% to $12.5 million in 2024, then plunged by 60.21% to $5.0 million in 2025, then fell by 9.77% to $4.5 million in 2026.
- The last three Other Accumulated Expenses figures came in at $4.5 million (Q2 2026), $5.0 million (Q4 2025), and $5.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.48 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Dec 31, 2024 | 12.48 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Dec 31, 2023 | 10.48 Mn |
| Jun 30, 2023 | 6.81 Mn |
| Dec 31, 2022 | 12.21 Mn |
| Jun 30, 2022 | 37.25 Mn |
| Dec 31, 2021 | 17.19 Mn |
| Jun 30, 2021 | 6.86 Mn |
| Mar 31, 2021 | 5.58 Mn |
| Dec 31, 2020 | 4.38 Mn |
| Jun 30, 2020 | 3.93 Mn |
| Dec 31, 2019 | 5.86 Mn |
| Sep 30, 2019 | 4.07 Mn |
| Jun 30, 2019 | 5.36 Mn |
| Mar 31, 2019 | 3.21 Mn |
| Dec 31, 2018 | 26.61 Mn |
| Jun 30, 2018 | 31.16 Mn |